CareDx Q3 revenue $82.9M (+23% YoY), raises FY guidance to $327-331M with positive EBITDA $6.9M

CareDx, Inc.

2024-Q3 EPS reported -$0.49 revenue$247,206,000

Revenue $82.9M (+23% YoY); testing services rev $60.8M (+27%); volume 44,600 tests (+16%).
GAAP net loss $7.4M improved from -$23.5M; non-GAAP net income $8.0M; positive adjusted EBITDA $6.9M.
Raised FY2024 revenue guidance to $327-331M (from $320-328M) and adjusted EBITDA to $18-22M (from $9-15M).
DOJ concluded investigation with no finding of wrongdoing; CMS reaffirmed coverage for AlloSure/AlloMap.
Cash $241M, no debt; hired new COO, CCO, and Chief Data/AI Officer.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.